Recce Pharmaceuticals Ltd
ASX: RCE.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Hamilton-Bray Graham
- Headquarters
- Sydney, Australia
- IPO year
- 2016
- Market cap
- A$144.6M
- Website
- https://www.recce.com.au
Loading RCE…
Loading profile data…Frequently asked questions about RCE
What does Recce Pharmaceuticals Ltd (RCE.AX) do?
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug...
Where does RCE.AX trade?
Recce Pharmaceuticals Ltd (RCE.AX) trades on the Australian Securities Exchange.
What sector is RCE.AX in?
Recce Pharmaceuticals Ltd (RCE.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Recce Pharmaceuticals Ltd?
James Hamilton-Bray Graham is the chief executive officer of Recce Pharmaceuticals Ltd (RCE.AX).
Where is Recce Pharmaceuticals Ltd headquartered?
Recce Pharmaceuticals Ltd is headquartered in Australia.
Does RCE.AX pay a dividend?
Recce Pharmaceuticals Ltd (RCE.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RCE.AX go public?
Recce Pharmaceuticals Ltd (RCE.AX) completed its initial public offering in 2016.